Found 31 articles for: "Cutaneous"
Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study
August 2026 | Volume 25 | Issue 8 | Original Article | 732 | Copyright © August 2026
Background: Acne is a common cutaneous adverse event associated with Janus kinase (JAK) inhibitors, with incidence varying across agents. Substantial increase in JAK inhibitor us...
Read MorePigmented Basal Cell Carcinoma in Skin of Color: A Systematic Review of the Literature
July 2026 | Volume 25 | Issue 7 | Original Article | 605 | Copyright © July 2026
Background: Though basal cell carcinoma (BCC) is most often studied in Fitzpatrick Skin Types (FST) I-III, BCC in skin of color (SOC) is characterized by unique clinical features...
Read MoreLatin America Cutaneous Oncology Management (LACOM) II: A Practical Algorithm for Managing Skin Toxicities in Oncology Patients
July 2026 | Volume 25 | Issue 7 | Original Article | 621 | Copyright © July 2026
Background: Anticancer treatments are associated with cutaneous adverse events (cAEs) that can severely impact patients' quality of life (QoL) and interfere with treatment outcom...
Read MorePerioperative Use of Angiotensin Inhibitors and Their Complications in Mohs Surgery: A Retrospective Cohort Study
June 2026 | Volume 25 | Issue 6 | Features | e51 | Copyright © June 2026
Predicting Benefit of Adjuvant Radiation Therapy for Cutaneous Squamous Cell Carcinoma: A Systematic Review
June 2026 | Volume 25 | Issue 6 | Original Article | 502 | Copyright © June 2026
Background: Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent skin cancer, and its incidence has been rising.Certain patients with high-risk cSCC...
Read MoreEfficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel
May 2026 | Volume 25 | Issue 5 | Original Article | 413 | Copyright © May 2026
Background: Cutaneous squamous cell carcinoma (cSCC) represents a significant clinical challenge in patients with locally advanced (laCSCC) or metastatic (mCSCC) disease who are ...
Read MoreEfficacy and Safety of Topical Metformin vs Kligman Formula in the Treatment of Melasma: A Split-Face Study
May 2026 | Volume 25 | Issue 5 | Original Article | 435 | Copyright © May 2026
Background: Melasma is an acquired pigmentary disorder characterized by symmetrical hyperpigmented macules and patches on sun-exposed areas, primarily the face. Kligman's formula...
Read MorePembrolizumab as an Off-Label Treatment of Facial Angiosarcoma: A Case Report
May 2026 | Volume 25 | Issue 5 | Case Reports | 471 | Copyright © May 2026
Summary of Case: We report an atypical case of cutaneous angiosarcoma presenting as unilateral nasal swelling in an elderly male. The lesion was unresponsive to topical and antib...
Read MoreThe Dermoepidermal Junction as the Initiation Point for Reversal of Dermatoporosis
April 2026 | Volume 25 | Issue 4 | Original Article | 377 | Copyright © April 2026
Background: Dermatoporosis (DP) or chronic cutaneous fragility syndrome has traditionally been linked to extracellular matrix (ECM) dehydration, reduced cellular turnover, epider...
Read MoreConnecting the Plaques: Exploring the Link Between Dupilumab and Cutaneous T-cell Lymphoma
November 2025 | Volume 24 | Issue 11 | Features | 1148 | Copyright © November 2025
The Emerging Role of Oncodermatology in a Hemato-Oncology Unit in a Tertiary Hospital
October 2025 | Volume 24 | Issue 10 | Original Article | 1018 | Copyright © October 2025
Background: Our dermatology department consistently receives the largest proportion of internal on-call referrals from the Hematology-Oncology Department. Individuals with hemato...
Read MoreA Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies
April 2025 | Volume 24 | Issue 4 | Features | 413 | Copyright © April 2025
Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. There is a lack o...
Read MoreLatin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors
March 2025 | Volume 24 | Issue 3 | Original Article | 262 | Copyright © March 2025
Background: Cancer-treatment-related cutaneous adverse events (cAEs) are common and may severely impact quality of life (QoL) and decrease treatment outcomes. The Latin American ...
Read MoreEffects on the Skin Microbiome by a Moisturizer Formulated for Eczema-Prone and Sensitive Skin
March 2025 | Volume 24 | Issue 3 | Original Article | 275 | Copyright © March 2025
Background: Cutaneous dysbiosis contributes to the pathophysiology of atopic dermatitis and potentially that of sensitive skin; regulation of the bacterial communities through sk...
Read MoreDifferentiating and Managing Cutaneous Lupus Erythematosus-Associated Alopecia and Patchy Alopecia Areata: Therapeutic Insights From Case Studies
March 2025 | Volume 24 | Issue 3 | Case Reports | 324 | Copyright © March 2025
Cutaneous lupus erythematosus (CLE) is an autoimmune disease with diverse clinical manifestations, including patchy hair lossresembling alopecia areata (AA). This report describes tw...
Read MoreThe Role of JAK Inhibitors in the Treatment of Cutaneous Lupus Erythematosus: A Review
December 2024 | Volume 23 | Issue 12 | Original Article | 1100 | Copyright © December 2024
Cutaneous lupus erythematosus (CLE), a manifestation of the chronic autoimmune disease lupus erythematosus (LE), showcases diverse clinical, immunologic, and histologic attributes. CLE can be fur...
Read MoreCutaneous Collagenous Vasculopathy Treated With Pulsed Dye Laser: A Case Series and Literature Review
December 2024 | Volume 23 | Issue 12 | Case Reports | 1121 | Copyright © December 2024
Cutaneous collagenous vasculopathy (CCV) is an underreported cutaneous microangiopathy that primarily involves the lower extremities. Optimal treatment of CCV has not been well-defined, which may...
Read MoreFunctional and Cutaneous Treatment Outcomes With Intravenous Immunoglobulin for Eosinophilic Fasciitis: A Retrospective Study
April 2024 | Volume 23 | Issue 4 | Editorials | e107 | Copyright © April 2024
Background: Eosinophilic fasciitis (EF) is a rare subtype of deep morphea with an elevated risk of functional impairment. No treatment algorithm has been established for adults w...
Read MoreOff-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases
December 2023 | Volume 22 | Issue 12 | Original Article | 1183 | Copyright © December 2023
Dysregulation of Janus kinase (JAK) pathways from uncontrolled cytokine signaling comprises the pathological basis for many complex inflammatory cutaneous disorders. Oral JAK inhibitors, upadacit...
Read MoreInnate Error Immunities of the Th17 Immune Pathway Associated With Chronic Mucocutaneous Candidiasis: A Systematic Review
December 2023 | Volume 22 | Issue 12 | Original Article | 1197 | Copyright © December 2023
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
